ORF6, a repressor of the MHC class I pathway: new molecular target for SARS-CoV-2 drug discovery?

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2023-07-01 Epub Date: 2023-08-30 DOI:10.1080/14728222.2023.2248377

Baohui Zhu, Ryota Ouda, Paul de Figueiredo, Koichi S Kobayashi

引用次数: 0

Abstract

Department of Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, and Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, USA; Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Sapporo, Japan; Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, TX, USA

查看原文本刊更多论文

ORF6，MHC I类通路的阻遏物：严重急性呼吸系统综合征冠状病毒2型药物发现的新分子靶点？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.